Business
Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women’s Cancers
Plenary oral presentation features long-term follow-up data from the Phase 2 RAMP 201 recurrent low-grade serous ovarian cancer clinical trial
About this update from Verastem, Inc.
[{"type":"text","content":"\nPlenary oral presentation features long-term follow-up data from the Phase 2 RAMP 201 recurrent low-grade serous ovarian cancer clinical trial\n\n\n BOSTON--(BUSINESS WIRE)--\nVerastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced it will present new long-term AVMAPKI™ FAKZYNJA™ combination therapy (avutometinib capsules; defactinib tablets) data from the Phase 2 RAMP 201 clinical trial at the Society of Gynecologic Oncology (SGO) 2026 Annual Meeting on Women’s Cancers. Additional abstracts accepted for presentation will also be shared at the meeting being held on April 10-13, 2026, in San Juan, Puerto Rico.\n\n\n“We look forward to the upcoming data presentation at SGO, which includes an additional year of follow-up data beyond the initial presentation of this important study,” said John Hayslip, M.D., chief medical officer at Verastem Oncology. “These results reinforce the findings from the RAMP 201 primary analysis of avutometinib in combination with defactinib and continue to add to the clinical body of evidence demonstrating the long-term safety and efficacy of this combination for patients with recurrent LGSOC with and without KRAS mutations.”\n\n\nVerastem will have an exhibition booth (#608) at the meeting to provide an overview of its approved therapy and ongoing cancer research. The full schedule and poster titles are available online at the SGO 2026 Annual Meeting on Women’s Cancer website.\n\n\nOral Plenary Presentation Details\nSession: Scientific Plenary I: Advancing Science through Clinical Trials\nTitle: Long-Term Efficacy and Safety of Avutometinib + Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer: Results from ENGOT-OV60/GOG-3052/RAMP 201\nPresenter: Rachel Grisham, M.D., Memorial Sloan Kettering Cancer Center\nDate and Time: Friday, April 10, 2026, 5:05 pm - 5:13 pm\nLocation: Exhibit Hall A\n\n\nPoster Presentation Details\nSession: Poster\nTitle: Exposure-Response Analysis for Avutometinib in Combination with Defactinib in Low-Grade Serous Ovarian Cancer\nPresenter: Yaofeng Cheng, Ph.D., Verastem Oncology\nDate: Sunday, April 12, 2026\nPoster # and Location: #1112, Exhibit Hall B\n\n\nSession: Poster Tour\nTitle: Combination targeted and Hormonal treAtMEnt of Low-gradE se...